红细胞生成素治疗晚期头颈部恶性肿瘤相关贫血的临床观察被引量：1

导出

摘要目的观察重组人红细胞生成素（Epo）治疗头颈部恶性肿瘤相关贫血的效果和对生活质量的影响。方法病理确诊的晚期头颈部恶性肿瘤相关贫血患者18例，接受rHuEpo6000u，每周2-3次皮下注射，连续治疗4WK，观察治疗前后患者贫血状况的变化和治疗安全性。对照组：19例，采用输血和一般支持疗法。应用卡氏功能状态（KPS）对贫血患者进行治疗前后的生活质量评分评定。结果Epo治疗能显著提高晚期头颈部恶性肿瘤相关贫血患者的血红蛋白水平、改善患者生活质量。在治疗观察过程未出现不能耐受的不良反应。结论使用Epo能够有效提高晚期头颈部恶性肿瘤相关贫血患者的血红蛋白水平，改善患者生活质量。

作者方国全徐源朱爱萍王艺

机构地区安徽省安庆市第一人民医院

出处《中国中西医结合耳鼻咽喉科杂志》 2009年第2期103-104,共2页 Chinese Journal of Otorhinolaryngology in Integrative Medicine

关键词恶性肿瘤红细胞生成素贫血

分类号 R739.91 [医药卫生—肿瘤]

引文网络
相关文献

参考文献4

1上海市血液学会多发性骨髓瘤协作组,梁晓华,林果为.红细胞生成素治疗多发性骨髓瘤贫血的疗效观察[J].临床血液学杂志,2000,13(5):210-211. 被引量：4
2李建彬,马志芳.红细胞生成素在恶性肿瘤放射治疗中的应用[J].国外医学（输血及血液学分册）,1999,22(1):14-16. 被引量：5
3王文,张茂宏,徐从高.Epo和铁代谢与恶性肿瘤贫血[J].中华血液学杂志,2001,22(4):222-224. 被引量：27
4李睿,吴晴,陆舜,张凤春,金冶宁,王杰军.重组人红细胞生成素-α治疗恶性实体瘤相关贫血的临床研究[J].肿瘤,2008,28(2):132-135. 被引量：10

二级参考文献10

1Leng H M J，Exp Hematol，1999年，27卷，806页
2Dai C H，Blood，1998年，91卷，1235页
3Weiss G，Blood，1997年，89卷，680页
4RALPH B, IMTIAZ A M, VINAY R, et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia[ J]. Oncologist,2006,11 (4) : 409-417.
5IAN Q, MICHAEL K, FELIX C, et al. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion : an integrated analysis of the canadian experience [ J ]. Oncologist, 2006, 11 ( 1 ) : 73-82.
6KOTASEK D, STEGER G, FAUGHT W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study [ J ]. Eur J Cancer,2003, 39 (14) : 2026-2034.
7VADHAN-RAJ S, MIRTSCHING B, CHARU V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks [ J ]. J Support Oncol , 2003,1 (2) : 131-138.
8GABRILOVE J L, CLEELAND C S, LIVINGSTON R B,et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing[ J ]. J Clin Oncol,2001,19 ( 11 ):2875-2882.
9BOHLIUS J, WILSON J, SEIDENFELD J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients [ J ]. J Natl Cancer lnst, 2006, 98 (10) : 708-714.
10BENNETT C L, COURNOYER D, CARSON K R, et al. Longterm outcome of individuals with pure red cell aplasia and anitery- thropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the research on adverse drug events and reports (RADAR) project[ J]. Blood,2005,106(10) : 3343-3347.